ABCB1 genotype and PGP expression, function and therapeutic drug response:: a critical review and recommendations for future research

被引:219
作者
Leschziner, G. D.
Andrew, T.
Pirmohamed, M.
Johnson, M. R.
机构
[1] Univ London Imperial Coll Sci Technol & Med, Div Neurosci, Charing Cross Hosp, London W6 8RF, England
[2] Wellcome Trust Sanger Inst, Cambridge, England
[3] Univ Liverpool, London, England
基金
英国惠康基金;
关键词
ABCB1; MDR1; drug response; PGP function;
D O I
10.1038/sj.tpj.6500413
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The product of the ABCB1 gene, P-glycoprotein (PGP), is a transmembrane active efflux pump for a variety of drugs. It is a putative mechanism of multidrug resistance in a range of diseases. It is postulated that ABCB1 polymorphisms contribute to variability in PGP function, and that therefore multidrug resistance is, at least in part, genetically determined. However, studies of ABCB1 genotype or haplotype and PGP expression, activity or drug response have produced inconsistent results. This critical review of ABCB1 genotype and PGP function, including mRNA expression, PGP-substrate drug pharmacokinetics and drug response, highlights methodological limitations of existing studies, including inadequate power, potential confounding by co-morbidity and co-medication, multiple testing, poor definition of disease phenotype and outcomes, and analysis of multiple drugs that might not be PGP substrates. We have produced recommendations for future research that will aid clarification of the association between ABCB1 genotypes and factors related to PGP activity.
引用
收藏
页码:154 / 179
页数:26
相关论文
共 129 条
  • [1] Alonso-Villaverde C, 2005, AIDS, V19, P341
  • [2] Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy
    Anglicheau, D
    Le Corre, D
    Lechaton, S
    Laurent-Puig, P
    Kreis, H
    Beaune, P
    Legendre, C
    Thervet, E
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) : 595 - 603
  • [3] CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
    Anglicheau, D
    Thervet, E
    Etienne, I
    De Ligny, BH
    Le Meur, Y
    Touchard, G
    Büchler, M
    Laurent-Puig, P
    Tregouet, D
    Beaune, P
    Daly, A
    Legendre, C
    Marquet, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) : 422 - 433
  • [4] Testing for population subdivision and association in four case-control studies
    Ardlie, KG
    Lunetta, KL
    Seielstad, M
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (02) : 304 - 311
  • [5] Asano Takeshi, 2003, Pharmacogenetics, V13, P675, DOI 10.1097/00008571-200311000-00003
  • [6] Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
    Baker, EK
    Johnstone, RW
    Zalcberg, JR
    El-Osta, A
    [J]. ONCOGENE, 2005, 24 (54) : 8061 - 8075
  • [7] Effect of grapefruit juice on digoxin pharmacokinetics in humans
    Becquemont, L
    Verstuyft, C
    Kerb, R
    Brinkmann, U
    Lebot, M
    Jaillon, P
    Funck-Brentano, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 311 - 316
  • [8] The association of common SNPs and haplotypes in the CETP and MDRI genes with lipids response to fluvastatin in familial hypercholesterolemia
    Bercovich, D
    Friedlander, Y
    Korem, S
    Houminer, A
    Hoffman, A
    Kleinberg, L
    Shochat, C
    Leitersdorf, E
    Meiner, V
    [J]. ATHEROSCLEROSIS, 2006, 185 (01) : 97 - 107
  • [9] HMG-CoA reductase inhibitors and P-glycoprotein modulation
    Bogman, K
    Peyer, AK
    Török, M
    Küsters, E
    Drewe, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) : 1183 - 1192
  • [10] MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients
    Bonhomme-Faivre, L
    Devocelle, A
    Saliba, F
    Chatled, S
    Maccario, J
    Farinotti, R
    Picard, V
    [J]. TRANSPLANTATION, 2004, 78 (01) : 21 - 25